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Human immunodeficiency virus and other lentiviruses infect cells independent of cell cycle progression, but
gammaretroviruses, such as the murine leukemia virus (MLV) require passage of cells through mitosis. This property is
thought to be important for the ability of HIV to infect resting CD4þT cells and terminally differentiated macrophages.
Multiple and independent redundant nuclear localization signals encoded by HIV have been hypothesized to facilitate
migration of viral genomes into the nucleus. The integrase (IN) protein of HIV is one of the HIV elements that targets to
the nucleus; however, its role in nuclear entry of virus genomes has been difficult to describe because mutations in IN
are pleiotropic. To investigate the importance of the HIV IN protein for infection of non-dividing cells, and to
investigate whether or not IN was redundant with other viral signals for cell cycle-independent nuclear entry, we
constructed an HIV-based chimeric virus in which the entire IN protein of HIV was replaced by that of MLV. This
chimeric virus with a heterologous IN was infectious at a low level, and was able to integrate in an IN-dependent
manner. Furthermore, this virus infected non-dividing cells as well as it infected dividing cells. Moreover, we used the
chimeric HIV with MLV IN to further eliminate all of the other described nuclear localization signals from an HIV
genome—matrix, IN, Viral Protein R, and the central polypurine tract—and show that no combination of the virally
encoded NLS is essential for the ability of HIV to infect non-dividing cells.
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Introduction
Human immunodeﬁciency virus and other lentiviruses
have the ability to infect non-dividing cells [1–3]. This
property allows HIV to integrate into two major types of
virus reservoirs in vivo: resting CD4þ T cells and macro-
phages [4]. However, the ability to productively infect non-
dividing cells is not shared by all retroviruses [5]. For
example, the gamma retroviruses as exempliﬁed by the
murine leukemia virus (MLV) requires mitosis for integration
[6,7]. Infection and transduction with foamy retroviruses also
depends on cell cycle and requires mitosis [8–10]. An
alpharetrovirus, the avian sarcoma virus, appears to be able
to integrate viral genomes in non-dividing cells [11,12], but
fails to produce virus particles, indicating that it requires
mitosis for a later stage of the viral life-cycle [13,14].
After entry into the cytoplasm, retroviruses undergo an
uncoating and reverse transcription process that yields a
large nucleoprotein complex called the preintegration com-
plex (PIC) [15]. Nuclear entry of viral DNA is an essential step
in the retroviral life cycle since viral genomic DNA in the PIC
must enter the nucleus to be integrated into host cell
chromosomes. The prevailing model to explain the ability
of lentiviruses to infect cells independent of the cell cycle is
that lentiviruses can target their viral genomes into the
nucleus of non-dividing cells via active nuclear transport,
while gammaretroviruses that cannot infect non-dividing
cells gain an access to the host chromosomes only when the
nuclear membrane breaks down at mitosis [6,7]. Thus, it has
been hypothesized that the PIC of lentiviruses contain virally
encoded nuclear localization signals (NLS), which allow active
nuclear transport independent of the cell cycle, whereas the
PIC of gammaretroviruses do not contain virally encoded
NLS, and thus can not enter the nucleus until mitosis
(reviewed in [16]).
Several lentiviral elements that contain a potential NLS
and are present in the PIC have been identiﬁed including the
matrix (MA) [17], integrase (IN) [18], and Viral Protein R
(Vpr) [19] proteins and a cis-acting element called the central
polypurine tract (cPPT) [20]. However, the importance of
each of these elements is controversial since subsequent
studies have shown that HIV lacking one or several mutations
in these NLS elements still retains a signiﬁcant ability to
infect non-dividing cells [16,21–27]. The IN protein is a
particularly attractive candidate to mediate nuclear import
of HIV genomes since it is part of the PIC through all steps of
infection until viral integration, and IN is necessary for
nuclear localization and transposition of the yeast elements
Ty1 and Ty3 [28–30]. Moreover, HIV IN contains nuclear
import activity [18,25,31–34], whereas MLV IN lacks such
nuclear import activity [35,36]. However, the role of HIV IN
within nuclear import of viral genomes has been difﬁcult to
deﬁnitively address because mutations or deletions within IN
often show pleiotropic effects on virus replication, including
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tion (reviewed in [37]). Recent work has suggested that HIV
IN itself does not contain an NLS, but rather trafﬁcs to the
nucleus by virtue of binding the lens epithelium-derived
growth factor (LEDGF)/p75 protein [36,38–39].
We recently reported that the capsid protein (CA) is a
dominant determinant of retroviral infectivity in non-divid-
ing cells since HIV containing MLV CA lost the ability to
infect non-dividing cells, even though it still contains proteins
with an NLS [40]. Because HIV CA is not nucleophilic [41,42]
and is not stably associated with the HIV PIC [43–48], these
data led us to propose that nuclear entry is not the rate-
limiting step in the ability of HIV to infect non-dividing cells
[40,49]. However, because we were unable to eliminate all of
the proposed NLS in HIV, we could not rule out the
possibility that the chimeric HIV containing MLV CA masked
a pathway usually used by HIV for entry into the nucleus.
Here, we directly tested the involvement of IN within
infection of non-dividing cells by constructing an HIV-MLV
chimeric virus in which the HIV IN coding sequence was
replaced with the IN coding sequence of MLV. Somewhat
remarkably, this chimeric virus was infectious at a low level
and was able to integrate in an IN-dependent manner.
Furthermore, this virus infected non-dividing cells as well as
it infected dividing cells.
While individual NLS-containing proteins, in some cases
combinations, have been mutated or deleted from HIV in
previous studies, it could be argued that the effect of the
different NLS are redundant, and therefore HIV still retained
some abilitytoinfectnon-dividingcellsbecauseofthepresence
ofother NLS onotherproteins. The ability to generate anHIV-
based chimera with MLV IN allowed us to further eliminate all
of the other described NLS (MA, Vpr, and the cPPT) from an
HIV infectious clone. We report here that this chimeric virus
without any of the previously described NLS is still able to
infect non-dividing cells. We discuss the possibility that
uncoating of the entering viral particle, rather than nuclear
import, is the rate-limiting step that determines the cell cycle
dependence/independence of retroviral infections.
Results
Generation of an Infectious Chimeric HIV-1 with MLV IN
That Is Integration-Competent
HIV IN localizes to the nucleus when stably expressed in
cells, whereas MLV IN does not [36]. Therefore, to determine
if the karyophilic property of IN is essential for the infectivity
of HIV in non-dividing cells, HIV-1 IN was replaced with
MLV IN within an HIV-based provirus, generating the
chimeric clone called MHIV-mIN (which encodes MLV IN
instead of HIV IN while the rest of the provirus is HIV)
(Figure 1). Transfection of this chimeric provirus showed that
it produces virus particles as indicated by the presence of
virus-speciﬁc proteins in culture supernatants of transfected
cells (Figure 2). As expected, MLV IN, and not HIV-1 IN, was
detected in virions (Figure 2). The amount of virions made by
MHIV-mIN was between 3- to 30-fold lower than that made
by wild-type HIV-1 as measured by p24gag ELISA (unpub-
lished data). Nevertheless, processing of reverse transcriptase
(RT) and IN appeared normal in virions produced by MHIV-
mIN virus (Figure 2).
We tested the infectivity of MHIV-mIN together with wild-
type HIV-1 in a single-cycle replication assay [50]. While the
titer of MHIV-mIN was about 3-logs lower than that of wild-
type HIV-1 when normalized by the amount of p24gag
(Figure 3A), it was still well above the background. Real-time
PCR data indicated that MHIV-mIN produces 3- to 5-fold less
cDNA than wild-type HIV-1 (Figure 3B). Thus, a decrease of
reverse transcription of MHIV-mIN alone cannot explain the
reduced infectivity of MHIV-mIN.
The integration reaction requires speciﬁc recognition by
viral IN of short DNA sequences (;10 bp) at both ends of
viral DNA, called the attachment (att) site. A previous report
indicated that replacement of HIV att sites with MLV att sites
at both ends of the long terminal repeat (LTR) reduced viral
titer to 0.5% level of the wild-type level [51], while others
have found that the att sequences other than the conserved
CA dinucleotide motif are not very important in vivo [52,53].
To test this, we also made a chimeric clone that contains MLV
att sequences in both ends of the LTR (Figure 1, called
pMHIV-mIN/matt), and examined the infectivity of these
chimeras (Figure 3C). We could obtain titers of up to 1 310
6
infectious units per ml after concentration of both viruses,
but MHIV-mIN/matt did not show any signiﬁcant increase in
infectivity when compared with MHIV-mIN (Figure 3C). The
infectivity of MHIV-mIN was also sensitive to reverse tran-
scriptase inhibitors (Figure 3C and Figure S1), and thus
depends on de novo genomic DNA synthesis. Therefore, we
found that there is not a requirement for an MLV-speciﬁc att
site in the context of a chimeric HIV with MLV IN.
IN mutants of HIV that are defective for integration
support low levels of infectivity in the multinuclear
activation of galactosidase indicate cell (MAGI) assay,
probably due to weak expression of the tat gene products
from unintegrated DNA [54–56]. However stable expression
of transduced genes usually requires integration of viral
DNA into host chromosome [57,58]. Thus, to genetically test
for integration, we made use of a reporter virus system in
which the puromycin-resistant gene was put in place of the
nef gene, and infected cells were selected for puromycin
resistance. Compared with HIV, MHIV-mIN exhibits ;4 log
decrease of infectivity in the puromycin-based assay (Figure
3D), which is about one log lower than the virus titer
difference in MAGI assay (Figure 3A). The difference
between the MAGI titer and the puromycin-resistance titer
is likely due to expression of Tat from unintegrated DNA
[54–56]. Nonetheless, these data show that MHIV-mIN is
capable of stable transduction.
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Synopsis
Human immunodeficiency virus can infect many cells irrespective of
whether or not they are dividing, whereas some other retroviruses,
such as the murine leukemia virus can only infect cells that are
proliferating. This property is important for the ability of HIV to
establish infections in critical cell types in infected people. Multiple
and redundant signals encoded by HIV have been hypothesized to
facilitate migration of viral genomes into the nucleus. However, here
the authors eliminated all four described nuclear localizing signals
from an HIV genome and show that no combination of these virally
encoded signals is essential for the ability of HIV to infect non-
dividing cells. They suggest that another step of the virus lifecycle,
other than nuclear import, is the rate-limiting step that determines
the cell cycle dependence/independence of retroviral infections.To more directly address the question of whether or not
the MHIV-mIN virus can carry out bona ﬁde IN-mediated
integration, we extracted genomic DNA from the puromycin-
resistant colonies to amplify and sequence the junction
between viral and host sequences. There are two character-
istic features of retroviral integration of viral DNA into the
host genome. First, two nucleotides are deleted from both
ends of viral DNA. Indeed, we observed the deletion of two
nucleotides of both ends of all sequenced clones (Figure 4).
The second characteristic of IN-mediated integration is that
the target sequence of the host DNA is duplicated after the
integration event. The size of duplication differs among
retroviruses [59]; for example, HIV integration yields 5-bp
duplication of the target sequence, whereas MLV integration
creates 4-bp duplication. In each case, the length of the
duplicated sequence was 4-bp, which is consistent with
integration of the HIV chimeric virus mediated by the MLV
IN. Taken together these ﬁndings demonstrate that MHIV-
mIN is competent for all of the early steps of virus replication
including integration.
HIV IN Is Not Essential for Infection of Non-Dividing Cells
HIV efﬁciently infects non-dividing cells, whereas MLV
infection is restricted in non-dividing cells. To determine if
IN plays an essential role in this difference, growth-arrested
cells prepared by treatment of HeLa cells with aphidicolin
were challenged with the chimeric virus MHIV-mIN along
with control viruses, and infectivity was judged by measuring
the output of the luciferase gene encoded by reporter virus
constructs. As expected from previous studies, wild-type HIV
was capable of infecting non-dividing cells as efﬁciently as
dividing cells, while transduction of the luciferase gene by
MLV was reduced in non-dividing cells compared with in
dividing cells (Figure 5). The phenotype of MHIV-mIN was
similar to that with HIV, but not with MLV, in that it was not
decreased in non-dividing cells relative to dividing cells
(Figure 5). In fact, we saw a slight increase of infectivity by
MHIV-mIN on non-dividing cells relative to dividing cells
(Figure 5). This increase may be due to expression of the
Figure 1. Schematic Representation of the Genomic Organization of Chimeric HIV/MLV Proviruses
Portions originated from the HIV genome are shown in white, while those from the MLV genome are in gray. The junction between HIV-1 RT and MLV
IN within HIV-mIN was created by direct joining of DNA sequences encoding the C-terminus of HIV RT to the N-terminus of MLV IN. Part of the 39 end of
the HIV-1 IN encoding sequence is retained in the construct of MHIV-mIN to preserve the overlapping Vif sequence and cis-acting elements such as
cPPT and splice acceptor(s). However, no part of HIV IN should be expressed in the chimeric virus because of the presence of two stop codons following
the sequence encoding MLV IN (see Materials and Methods). The molecular clone encoding MHIV-mIN/matt has the MLV att sites in 59 U5 and 39 U3.
After reverse transcription, both ends of U5 and U3 will have the MLV att sites. MHIV-mMA12CA has been previously described [40]. MHIV-mMA12CA/
mIN is similar except it contains MLV IN in addition to the MLV Gag region. A molecular clone of MHIV-mMA12CA/mIN was created by putting the DNA
sequence encompassing the MLV IN encoding sequence of the MHIV-mIN with a Vpr mutation into the infectious provirus pMHIV-mMA12CA. HIVDNLS
contains MLV MA instead of HIV MA, MLV IN instead of HIV IN and mutations in the cPPT and in Vpr.
DOI: 10.1371/journal.ppat.0010018.g001
Figure 2. Western Blot Analysis of Purified Virus Particles of MHIV-mIN
Together with HIV-1 and MLV
Polyprotein processing was tested for HIV-1 RT, HIV-1 IN and MLV IN.
Because of low protein production by MHIV-mIN, 10-times more virions
were loaded for MHIV-mIN than for HIV-1 and MLV in this experiment.
DOI: 10.1371/journal.ppat.0010018.g002
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as described in the case of infection of non-dividing cells with
feline immunodeﬁciency virus IN mutants [57]. Nonetheless,
these results demonstrate that IN is not an essential
determinant for the ability of HIV-1 to infect non-dividing
cells relative to dividing cells.
We previously showed that replacement of part of the gag
gene of HIV with that of MLV would convert HIV into a virus
that had lost the ability to infect non-dividing cells [40].
Similarly, we found that we can change the phenotype of the
MHIV-mIN by replacing the MA and CA proteins of HIV with
theMA, p12, and CA proteinsof MLV (MHIV-mMA12CA-mIN
in Figure 1). Indeed, addition of Gag proteins of MLV into the
HIV provirus that already contains MLV IN increased the
infectivity in dividing cells, but speciﬁcally lost the ability to
infect non-dividing cells (Figure 5: Compare MHIV-mMA12-
CA/mIN with MHIV-mIN). These data demonstrate that Gag,
rather than IN, is the dominant determinant for the ability of
HIV to infect cells independent of cell cycle progression.
Normal Levels of Nuclear Import by MHIV-mIN
A recent report showed that efﬁcient nuclear entry of HIV
can occur independently of mitotic nuclear disassembly in
cycling cells [60]. Thus, one interpretation of our results is
that elimination of an NLS from HIV would result in lack of
infectivity both in dividing and non-dividing cell populations.
Indeed, the new chimeric virus created in the present study,
MHIV-mIN, infects dividing cells and non-dividing cells with
an equal efﬁciency, but the overall infectivity by MHIV-mIN
is severely reduced from that of wild-type HIV-1 (Figure 3A).
Thus, to directly determine whether or not MHIV-mIN is
restricted at nuclear import of viral DNA, infected cells were
separated into cytoplasmic and nuclear fractions and real-
time PCR was used to measure late reverse transcription
products. The results indicate that there is little apparent
difference of viral DNA associated with nuclear fractions
between MHIV-mIN and HIV (Figure 6A). Although higher
Figure 4. Integration Sites of MHIV-mIN
A schematic illustration of the unintegrated viral DNA is shown with the
detailed structures of both ends of LTR (top). The two terminal base pairs
at each end of the linear DNA precursor, which are removed in the
integration process, as shown in highlight. Two other DNA sequences
confirmed the removal of dinucleotides from one end of viral DNA
(unpublished data). DNA sequences flanking integrated proviral DNA are
shown (bottom). Junction sequences between the integrated MHIV-mIN
genome and human genomic DNA at each end of the provirus were
obtained by nested PCR based on the sequence of integration sites that
were mapped with human genome sequences as described in the
Materials and Methods. The 4-bp sequence duplications that flank the
integrated provirus are shown in boxes.
DOI: 10.1371/journal.ppat.0010018.g004
Figure 3. MHIV-mIN Is Infectious
(A) Single-cycle infectivity of MHIV-mIN. VSV-G-pseudotyped HIV and
MHIV-mIN were made by transfection of 293T cells with plasmid DNA.
Infectivity was measured with the MAGI assay by counting b-
galactosidase positive cells 2 d post-infection. Virus titers were
normalized by the amount of p24 (lg). Infections were performed in
triplicate. Mean values are shown here with standard derivation. The
background in the assay is about 10 blue cells.
(B) Copy numbers of late products of reverse transcription were
measured by using real-time quantitative PCR. Viral cDNA numbers
were normalized by p24. Infections were performed in triplicate. This is a
representative experiment of three independent trials.
(C) Infectivity of MHIV-mIN and MHIV-mIN/matt was compared in the
MAGI assay. VSV-G-pseudotyped viruses were prepared and concen-
trated at 100-fold by ultracentrifugation. Infections of MAGI cells were
also performed in the presence or absence of reverse transcriptase
inhibitors (50 lM 3TC and AZT). Formation of blue cells in this assay must
result from retrovirus infection since addition of reverse transcription
inhibitors (shown as black bars) eliminated most of positive cells.
(D) Comparison of infectivity between wild-type HIV-1 and MHIV-mIN as
judged by the ability to make puromycin-resistant clones. Infectivity was
measured by counting puromycin-resistant colonies 14 d after infection.
To facilitate stable transduction of HIV genomes, a mutation was
introduced into the vpr gene in these proviruses because expression of
Vpr would preclude formation of colonies due to its cytotoxicity [69,77]
DOI: 10.1371/journal.ppat.0010018.g003
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fractions of HIV (;75%) than MHIV-mIN (;50%), this level
of difference cannot explain the decrease of infectivity by
MHIV-mIN (3-log reduction compared with wild-type HIV).
Control experiments using a cytoplasmic protein (LDH I) as a
maker for the cytoplasmic fraction indicated that contami-
nation of cytoplasm into the nuclear fraction is less than 1%
(Figure 6B. compare the 125-fold dilution of the cytoplasmic
fraction in lane 2 with the nuclear fraction in lane 6). These
data indicate that nuclear entry of MHIV-mIN is essentially
not inhibited and that reduced infectivity of the chimeric
virus is due to a post-nuclear entry event (most likely
integration). We also examined 2-LTR circles, which are
often used as a surrogate marker for nuclear entry. We found
that the ratio of 2-LTR circles to total viral DNA in cells
infected with MHIV-mIN is roughly equivalent (or even
slightly higher) to the ratio in cells infected with parental
HIV-1 (Figure 6C). The slight increase in the average number
of 2-LTR circles per total viral DNA for MHIV-mIN relative
to wild-type virus likely reﬂects the fact that mutants that
integrate inefﬁciently often accumulate 2-LTR circles [56].
Nonetheless, in sum, these data further support the idea that
HIV IN is not essential for the nuclear transport of viral DNA
and infectivity in non-dividing cells.
HIV Lacking All of the Known Types of NLS Still Infects
Non-Dividing Cells as Efficiently as Dividing Cells
As mentioned above, IN is not the sole candidate that
potentially encodes a viral NLS. MA, Vpr, and the cPPT have
all been described as elements that are important for entry of
HIV-1 PIC into the nucleus. To formally address the
argument that other described NLSs in HIV as well as the
cPPT are redundant for nuclear import with the NLS in HIV
IN, a mutant HIV-1 lacking all the NLS candidates was
generated. This mutant (HIV-DNLS), carrying MLV MA and
IN instead of HIV counterparts, lacks a functional vpr gene,
and has a mutated cPPT (Figure 1). We found that HIV-DNLS
had reduced infectivity relative to wild-type HIV (Figure 7),
but the infectivity of HIV-DNLS is sensitive to reverse
transcriptase inhibitors (Figure S1), and thus is not an artifact
of the virus concentration. Importantly, the infectivity of
HIV-DNLS is independent of cell cycle conditions (Figure 7).
It should be noted that our luciferase system can detect
reduction even when the activity is low (See reduction of
MLV infectivity in 0.08 ll in Figure 7, for example). The
phenotype of HIV-DNLS in non-dividing cells is in marked
contrast to that of MLV which is dependent on the cell cycle,
and in contrast to a previously described chimeric HIV virus
containing MLV MA, p12, and CA (MHIV-mMA12CA: Figure
1) [40], which has speciﬁcally lost the ability to efﬁciently
infect non-dividing cells (Figure 7). Therefore, these data
Figure 6. Nuclear Entry of MHIV-mIN
(A) Subcellular localization of viral DNA. Infected cells were fractionated
to cytoplasmic (C) and nuclear (N) fractions. Viral DNA was extracted and
subject to real-time PCR to measure late products of reverse tran-
scription. These data represent one of two independent experiments.
Control viruses, with the presence of reverse transcription inhibitors or
without VSV-G protein, were also used in the experiments to monitor
retrovirus-dependent DNA synthesis, and showed that contamination of
plasmid DNA used for transfection is less than 1% of the total DNA.
(B) Western blot analysis of total cell lysates (To), cytoplasmic extract (Cy)
and nuclear lysates (Nu). Contamination of cytoplasmic extract and the
presence of intact cells in nuclear fractions were tested by checking for
the presence of a cytoplasmic protein, LDH-I, in each fraction (upper
lanes). Five-fold dilutions of the cytoplasmic extract (5-, 25-, and 125-fold
dilutions, lanes 4, 3, and 2, respectively) were made to assess the degree
of contamination of the nuclear fraction. Presence of proteins was
confirmed by antibody against a nuclear pore complex protein (mAb414;
lower lane).
(C) Nuclear import was monitored by measuring late reverse tran-
scription products and 2-LTR circles. The ratio of total viral DNA and 2-
LTR circles was obtained by dividing the copy number of late RT
products by the copy number of 2-LTR circle. The parental wild-type
strain of HIV-1 (shown here as wt) was compared with the chimeric virus
MHIV-mIN (shown as mIN). Control infections with reverse transcription
inhibitors (AZT and 3TC: 50 lM each) yielded viral copy numbers that are
less than 10% of copy numbers of the samples without reverse
transcription inhibitors, indicating that contamination of plasmid DNA
used to produce virus stocks does not affect the final results. Two
independent experiments gave substantially identical data.
DOI: 10.1371/journal.ppat.0010018.g006
Figure 5. IN Does Not Determine the Infectivity in Non-Dividing Cells
Aphidicolin-treated HeLa cells were infected with increasing amount of
luciferase-encoding viruses described in Figure 1. Culture supernatants of
transfectedcellswereusedastheinoculum.Virusinfectivitywasjudgedby
measuring luciferase titers of infected cell lysates 2 d after infection. RLU;
relative light units. White circles indicate cells without aphidicolin. Filled
circles indicate cells with aphidicolin (2 lg per ml). This is a representative
experiment that was done at least three times for each virus.
DOI: 10.1371/journal.ppat.0010018.g005
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described NLS elements is fully capable of infecting non-
dividing cells as well as it infects dividing cells, and suggest
that the virally encoded NLS elements are not rate-limiting
for this process.
Discussion
In the present study, we created a chimeric HIV-1 in which
HIV IN is replaced by its counterpart from MLV and
demonstrated that HIV can integrate with a heterologous
IN protein. Thus, while inefﬁcient, MLV IN can replace HIV
IN within the context of an infectious virus. The infectivity of
this chimeric virus having MLV IN was not dependent on the
presence of the MLV att sites at the ends of the LTR, yet did
result in duplications of genomic DNA that were consistent
with MLV IN. We used this chimeric virus as a template to
eliminate all previously described viral NLS elements and
found that it was still able to infect non-dividing cells as well
as it infected dividing cells.
A popular model for lentiviral infection of non-dividing
cells is that the karyophilic activity of an HIV-encoded NLS
such as IN is important to bring HIV PIC into the nucleus of
non-dividing cells, thereby allowing efﬁcient infection in the
absence of mitosis. Our experiments using a chimeric HIV-1
with MLV IN showed that the exchange of IN does not cause
any phenotypic change of infectivity that is speciﬁc to non-
dividing cells. This ﬁnding indicates that IN is not an essential
determinant that governs the infectious phenotype in non-
dividing cells. These results are in agreement with some
previous studies that examined individual putative NLS
elements within HIV IN and argued against a role of an IN
NLS in nuclear import of HIV [16,24,25,61]. Indeed, a recent
report by Lu et al demonstrated that mutations in a putative
NLS of HIV IN results in class II mutations, which are
defective at a postnuclear entry step rather than at nuclear
import [61]. In contrast, Ikeda et al claimed that nuclear
import of viral DNA is affected by reduced binding of IN to
viral cDNA [62]. However, the reduction of nuclear import of
such IN mutants (with reduced binding ability to viral cDNA)
was at most 40% of the wild-type level as judged by nuclear
DNA and that amount of reduction does not seem to explain
severely reduced infectivity of their mutants (less than 1% of
the wild-type level) [62]. Moreover, other studies have shown
that HIV IN localizes to the nucleus by virtue of binding
LEDGF/p75 [36,38,39]. However, reduction of LEDGF levels
by small interfering RNA (siRNA) affected the nuclear
localization of HIV IN, but did not affect the ability of HIV
to infect non-dividing cells [36]. Therefore, although we
cannot completely rule out the possibility that HIV IN is
involved in nuclear migration of viral DNA, we believe that its
role is minor.
Although other studies have ruled out a role for individual
and some combinations of putative karyophilic viral elements
in the HIV PIC, it has not been possible up to now to
eliminate all of the identiﬁed elements at once in order to
test the hypothesis that infection of non-dividing cells is
reliant on multiple redundant NLS. However, we were able to
create an HIV mutant lacking all of the known NLS-encoding
elements, and demonstrated that not only IN, but also none
of the other NLS-encoding elements have any effect on the
ability of HIV-1 to infect non-dividing cells. Thus, our data
are not consistent with a previous suggestion that mutation of
single (or double) NLS-encoding elements had little pheno-
typic change because of redundant NLS-encoding elements
that are responsible for nuclear transport of HIV PIC and for
infection in non-dividing cells. One possible interpretation of
our results is that we have not yet found the most important
NLS encoded by HIV. While this is still formally possible, the
present results along with our previous results that found that
CA is a dominant determinant for retrovirus infectivity in
non-dividing cells [40], suggest that these virally encoded
karyophilic elements are not the major determinants for the
infectivity of HIV in non-dividing cells. Rather, we consider
that our data lend support to the alternative hypothesis that
nuclear entry is not the rate-limiting step for infection of
non-dividing cells. Our hypothesis is also consistent with the
ﬁndings that the addition of NLS encoding sequences to MLV
does not render it infectious to non-dividing cells [35,63].
Instead, we propose that the difference in CA between HIV
and MLV affects the progress of uncoating, thereby inﬂuenc-
ing downstream events such as nuclear import and integra-
tion. In this model, uncoating of HIV progresses normally in
non-dividing cells and functional PIC enter the nucleus
where they integrate viral DNA. In contrast, uncoating of
MLV is impaired in non-dividing cells, which results in the
failure of subsequent steps of the replication cycle. In this
scenario, gammaretroviruses may need mitosis to complete
uncoating. In fact, in the case of HIV, CA is dissociated from
Figure 7. HIV Lacking NLSs Infects Non-Dividing Cells
Single-cycle infectivity assay of HIV-DNLS together with HIV, MLV, and
MHIV-mMA12CA. Both HIV-DNLS and MHIV-mMA12CA were concen-
trated by ultracentrifugation for infections. For details, see the legend to
Figure 5. White circles indicate cells without aphidicolin. Filled circles
indicate cells with aphidicolin (2 lg per ml). This is a representative
experiment that was done at least 3 times for each virus.
DOI: 10.1371/journal.ppat.0010018.g007
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of CA are associated with MLV PICs [15,64–65], suggesting
that uncoating of MLV may not be as efﬁcient as that of HIV.
An optimal stability of the HIV core appears to be essential
for infectivity [66], and complete uncoating may be a
prerequisite for nuclear import of PIC. In this hypothesis,
the tight association of MLV CA with PIC prevents cellular
machinery from interacting with a putative NLS on MLV
PICs, thereby retaining PICs within the cytoplasm of
interphase cells. On the other hand, the HIV PIC can migrate
into the nucleus of interphase cells by using cellular transport
machinery. Thus, we are not arguing that nuclear import of
the HIV PIC is not essential. Rather, that it is not the rate-
limiting step and that cellular rather than viral components
of the PIC might play the major role in viral nuclear import
after uncoating.
Materials and Methods
Nomenclature and construction of proviruses. Proviruses were
named as follows: MHIV-mIN encodes the MLV IN instead of the HIV
IN while the rest of the provirus is HIV. MHIV-mIN/matt has the MLV
IN and MLV att sites. MHIV-MA12CA/mIN encodes the MLV IN as
well as the MA, p12, and CA proteins of MLV, instead of the HIV MA
and CA. HIV and MLV genes were taken from the infectious
proviruses pLai [67] and pAMS [68], respectively. The AMS clone
encodes a chimeric strain of amphotropic MLV of which 39 part of
the genome was obtained from the amphotropic virus clone 4070A
and the 59 end from MLV-K. The IN region derived from 4070A was
cloned into the proviral DNA of HIV-1 in place of part of the HIV IN
encoding sequence. The 59 end of the MLV IN encoding sequence
starts at the same position of the original 59 end of the HIV IN
encoding sequence. Therefore, the junction between the HIV RT
encoding sequence and the MLV IN encoding sequence is aggaaag-
tactaATAGAAAACTCAA (HIV sequence is shown in small letters;
MLV sequence is shown in capital letters). Part of the 39 end of the
HIV-1 IN encoding sequence was preserved in the construct of
MHIV-mIN, since it contains several important cis-acting elements
such as central polypurine tract (cPPT). The original TAA stop codon
for the MLV IN is followed by additional stop codon (TGA) that
prevents expression of a possible fusion protein containing MLV Env,
since MLV IN encoding sequence also contains the initiation site of
MLV Env. Thus, the junction between the MLV IN encoding sequence
and HIV sequence is CGTGGAAGCCCTTAATAGTCTgaattc (MLV
sequence is shown in capital letters; HIV sequence is shown in small
letters; two stop codons are shown in underlined).
A molecular clone of HIV-matt was constructed by replacing the att
sites of HIV with those of MLV in pLai. The 39 U3 att site of HIV-1
(ctggaagggcta) was replaced with the U3 att site of MLV (TGAAA
GACCCCAA). The 59 U5 att site of HIV-1 (tctctagcag) was replaced
with the U5 att site of MLV (ggtctttcat). Then, the clone HIV-matt was
used to create the construct encoding MHIV-mIN/matt by swapping
the DNA sequence encompassing the MLV IN encoding sequence in
the MHIV-mIN. An additional chimeric HIV-1 having both portion of
the gag gene and IN of MLV was made by replacing the DNA sequence
encoding the HIV MA and CA proteins with the DNA sequence of the
MLV MA, p12 and CA in the context of the proviral clone MHIV-
mIN, resulting in MHIV-mMA12CA/mIN.
An HIV mutant lacking all of the putative NLS encoding genes was
made by mutating the cPPT and the vpr gene and by replacing the
HIV-1 MA and IN with the MLV MA and IN, respectively. The cPPT-D
mutation [20] was introduced into pLai by PCR mutagenesis.
Construction of a Vpr mutant (pLai-DVpr) [69] and MHIV having
the MLV MA [40] was reported previously. All of these mutations and
replacements were combined together with the env-deﬁcient provirus
clone pLai-DEnv to create the NLS-minus mutant HIV-DNLS.
The reporter virus constructs encoding the luciferase gene were
made by introducing the luciferase gene from the wild-type Env-
minus HIV-1 (pLai-DEnv-luc2) [40] into the new HIV-based con-
structs. The puromycin resistant gene is cloned into the nef gene of
molecular clones of HIV-1, MHIV-mIN, and MHIV-Mma12CA/mIN.
The HIV puromycin resistant constructs were created in the same
way as the luciferase constructs as described above. The vpr mutant
pLai-DVpr was used to introduce an insertional mutation in the vpr
gene of the puromycin virus constructs.
Western blot analysis. Western blots were probed with the
following antibodies: rabbit anti-HIV-1 RT antibody (through the
AIDS Research and Reference Reagent Program, Division of AIDS,
NIAID); mouse monoclonal anti-HIV-1 IN antibody (Michael Malim,
King’s College, London); rabbit anti-MLV IN (Frederick Bushman,
University of Pennsylvania, [65]); sheep antibody against LDH I
(Cortex Biochem, San Leandro, CA); and mouse monoclonal antibody
against nuclear pore complex proteins MAb414 ( Covance, Devner,
Pennsylvania) [70]. The membranes were washed for 30 min in wash
buffer (PBS containing 0.2% Tween 20) and then incubated with a
1:10,000 dilution of horseradish peroxidase-conjugated antibodies
that match with the primary antibody for 60 min at room temper-
ature. The membranes were washed three times for 30 min, and the
bound antibody was detected with ECL Plus Western blotting
detection reagents (Amersham Biosciences, Little Chalfont, United
Kingdom). In some cases, membranes were stripped and reprobed
with another primary antibody.
Infectivity assays. Vesicular stomatitis virus G protein (VSV-G)-
pseudotyped viruses were prepared by transient transfections of
293T cells performed with the FuGene 6 reagent. HIV and MHIV
expression plasmids were co-transfected with a VSV-G-expression
vector (pL-VSV-G [71]) in addition to pCMV-tat to express the VSV-G
for pL-VSV-G. For the production of VSV-G-pseudotyped MLV, the
MLV Gag-Pol expression vector (pCS2-mGP) [40] were used along
with the murine retrovirus-based vectors [72] encoding the luciferase
gene (pLNCluc) [40] as well as the VSV-G construct. To enhance the
infectivity, MHIV-mIN and HIV-DNLS were concentrated by ultra-
centrifugation. Brieﬂy, 25–35 ml of culture supernatant of trans-
fected 293T cells were centrifuged at 5003g for 5 min to remove cell
debris and then ﬁltered through a 0.22 lm ﬁlter. The supernatant
were transferred into ultracentrifuge tubes and centrifuged at 64,000
3g for 90 min within a SW28 rotor (Beckman Instruments, Fullerton,
California, United States). The supernatants were carefully removed
and 250–350 ll of culture medium was added at 4 8C for 1 hr and
freshly used for infection.
Single-cycle infectivity of HIV and MHIV was measured by
challenging MAGI cells with serial dilution of virus and staining for
b-galactosidase expression as basically described previously [50].
HeLa cells were used for infections with the luciferase reporter virus
stocks. Luciferase titer was assayed with the luciferase assay kit
(Promega, Madison, Wisconsin, United States) and read on a
luminometer. Growth-arrested cells were prepared by treatment
with 2 lg per ml of aphidicolin (Sigma, St. Louis, Missouri, United
States). Virus binding was enhanced by spinoculation [73] and by
addition of 20 lg per ml of DEAE/dextran.
Quantiﬁcation of p24gag and viral cDNA. The p24gag content of
the viral supernatants was determined by an enzyme-linked immu-
nosorbent assay (ELISA; Beckman Coulter, Hialeah, Florida, United
States.). Late products of reverse transcription and 2-LTR circles of
HIV-1 were measured by using real-time PCR based on a previously
published protocol [74] as described previously [40].
Subcellular fractionation. One day before infection, approximately
5 million HeLa cells were seeded onto four 75 cm
2 ﬂasks. The cells
were challenged either by the VSV-G-pseudotyped HIV-1 or MHIV-
mIN. Cells were infected with virus stocks that can synthesize
equivalent amount of viral DNA in target cells. Virus stock of
MHIV-mIN was concentrated by ultracentrifugation. Both virus
stocks were treated with 50 units of Turbo DNase (Ambion, Austin,
Texas, United States) per ml at 37 8C for an hour. Infections were
performed with the presence of DEAE/dextran (20 lg per ml).
Subcellular fractionations were carried out based on the method
described by Yuan et al [75] with minor modiﬁcations. One day after
infection, cells were washed, tripsinized, and washed once again with
phosphate-buffered saline. In order to extract cell lysates and DNA
from intact cells, 20% of the infected cells were kept for further
experiments. All the manipulations after this step were carried out at
4 8C. The remaining 80% cells were resuspended in 3 volumes of
hypotonic buffer (10 mM HEPES, [pH 7.9]; 1.5 mM MgCl2; 10 mM KCl;
2 mM dithiothereitol ; 20 lg of aprotinin per ml). Resuspended cells
were centrifuged at 2,300 3 g for 5 min. The cell pellet was
resuspended in 3 volumes of hypotonic buffer and kept on ice for 10
min. The cells were homogenized with 30 strokes in a Dounce
homogenizer. Nuclei and cell debris were pelleted by centrifugation
at 3,300 3 g for 15 min. The supernatant of this centrifugation was
directly used to extract viral DNA or additionally spun down at
13,4003g for 20 min. The nuclear pellet were washed with 3 volumes
of hypotonic buffer containing 0.005% digitonin once and then
washed with hypotonic buffer twice. DNA was extracted from half of
each fraction using the QIAamp DNA Mini Kit (Qiagen, Valencia,
California, United States), and the other half was used for Western
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antibodies to a cytoplasmic protein or a nuclear pore antigen.
To assess the integrity of the fractionation procedure, we
examined the contamination of cytoplasmic fraction into nuclear
fraction by monitoring the presence of LDH I. Intact cells (10% of
the infected cells) and nuclei (half of the puriﬁed nuclei) were ﬁrst
resuspended with 50 ll and 100 ll of NTE buffer (10 mM Tris-HCl,
[pH 8.0]; 1 mM EDTA; 50 mM NaCl; 2 mM DTT; 20 lg of aprotinin
per ml), respectively. After incubation on ice for 5 min, equivalent
amount of NP40-doc buffer (1% NP40; 0.2% sodium deoxycholate;
0.12 M NaCl; 20 mM Tris-HCl, [pH 8.0]) were added to the samples
and kept on ice for 10 min. The samples were mixed by vortex and
spun down at 9,300 3 g for 5 min. Twenty lg of protein samples was
used in SDS-PAGE and western blotting analysis.
The most serious problem for our experiments was potential
contamination of cytoplasmic viral DNA into puriﬁed nuclei. Viral
DNA is present in a nucleoprotein complex or a free-DNA form, and
those viral DNA may behave differently than cytoplasmic proteins
such as LDH I in the process of fractionation. To address this
possibility, we used a control to determine if quantity of contami-
nation of viral DNA from the cytoplasmic fraction into the nuclear
fraction during the washing steps. To this end, we mixed cytoplasmic
extracts of infected cells with nuclei of uninfected cells. In these
experiments, we used MLV instead of HIV because of the ease of
manipulation. Virus stocks of MLV were prepared by harvesting
culture supernatant of ecotropic MLV-producing NIH/3T3 cells.
Cytoplasmic extracts of acutely infected cells and nuclei of
uninfected NIH/3T3 cells were prepared, mixed on ice, and washed
as described above. Nuclear-associated DNA was extracted and
subject to real-time PCR to measure the copy number of late reverse
transcription products as described above. We found that there was
less than 1% introduction of cytoplasmic viral DNA into the nuclear
fraction during the washing steps (unpublished data).
Sequencing of junctions between host DNA and integrated viral
DNA. Junction sequences between host DNA and viral DNA were
determined by using an inverse PCR strategy as described before [76].
HeLa cells were infected with VSV-G-pseudotyped MHIV-mIN-DVpr-
Puro. Puromycin-resistant cell clones (;130 colonies) were selected
for 2–3 weeks with the presence of puromycin (0.7 lg per ml) and
used to extract genomic DNA. Genomic DNA (2 lg) from infected
cells was digested with 20 U of PstI at 37 8C for 12 h. After heat
inactivation at 65 8C for 40 min, 200 ng of digested DNA were taken
out for ligation reaction. The ligation reaction was carried out at 16
8C for 12 h. Ligase was then heat inactivated at 65 8C for 15 min. The
region of the junction between cellular DNA and the 59 end of the
integrated proviral DNA was ampliﬁed by nested inverse PCR. The
ﬁrst PCR primers were U3RRG2, 59-GGCAAGCTTTATTGAGGC-
39and Gag716, 59-GGTCAGCCAAAATTACCCTATAGTG-39.T h e
second PCR primers were MH536, 59-TCCACAGATCAAGGA
TATCTTGTC-39, and Gag934, 59-TGTTAAAAGAGACCATCAAT
GAGGAAG-39. The PCR was carried out in 50 ll solution, which
contains 13PCR buffer, dNTPs (0.2 mM), primers (1 lM), 10 units of
Taq polymerase (Roche, Basel, Switzerland), and 200 ng of ligated
DNA. PCR products were puriﬁed and used for cloning by using
pGEM-T Vector System (Promega). Positive clones were sequenced by
using the T7 primer.
Junction sequences between 39 ends of viral DNA and host DNA
were determined for three of the clones by nested PCR with 59sense
primers matching with 39 LTR of proviral DNA and with 39 anti-sense
primers matching with host DNA downstream of viral DNA. The
information obtained from 59 junction sequences between host DNA
and viral DNA allowed us to map integration sites of these three
clones in the human genome sequence deposited in GenBank. Based
on this information, 39 primers were designed. Ampliﬁed products
were cloned into T-vector and sequenced.
Supporting Information
Figure S1. Single-Cycle Infectivity Assay of MHIV-mIN and HIV-
DNLS with Reverse Transcriptase Inhibitors
Infections with viruses that encode the luciferase gene in place of nef
were performed with the presence (shown in black) or absence
(shown in gray) of a reverse transcriptase inhibitor (RTI) (AZT and
3TC: 50 lM each). For details, see the legend to Figure 5. In both
cases, the luciferase activity is decreased by RTI which indicates that
expression of luciferase relies on de novo RT activity. Also, the
presence of aphidicolin does not change the dependence on de novo
reverse transcriptase activity for luciferase activity. This is a
representative experiment done with two different virus stocks with
virtually identical results.
Found at DOI: 10.1371/journal.ppat.0010018.sg001 (15 MB TIF).
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